Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia

Core-binding factor acute myeloid leukemia is characterized by t(8;21) or inv(16) and the fusion proteins RUNX1-RUNX1T1 and CBFB-MYH11. International guidelines recommend monitoring for measurable residual disease every 3 months for 2 years after treatment. However, it is not known whether serial mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Puckrin, Robert, Atenafu, Eshetu G., Claudio, Jaime O., Chan, Steven, Gupta, Vikas, Maze, Dawn, McNamara, Caroline, Murphy, Tracy, Schuh, Andre C., Yee, Karen, Sibai, Hassan, Minden, Mark D., Wei, Cuihong, Stockley, Tracy, Kamel-Reid, Suzanne, Schimmer, Aaron D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776265/
https://www.ncbi.nlm.nih.gov/pubmed/31896684
http://dx.doi.org/10.3324/haematol.2019.235721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776265/
https://www.ncbi.nlm.nih.gov/pubmed/31896684
http://dx.doi.org/10.3324/haematol.2019.235721

Ejemplares similares